Medicine and Dentistry
Neoplasm
100%
Lung Cancer
82%
Cancer
70%
Magnetic Resonance Imaging
47%
Metastatic Carcinoma
46%
Positron Emission Tomography-Computed Tomography
45%
Diseases
42%
Non Small Cell Lung Cancer
41%
Computer Assisted Tomography
41%
Malignant Neoplasm
36%
Radiation Therapy
33%
Mediastinum Mass
33%
Lung
28%
Immunotherapy
28%
Chest
27%
Diagnosis
25%
Thoracic Wall
22%
Biopsy Technique
20%
Esophageal Adenocarcinoma
20%
Targeted Therapy
19%
Chemoradiotherapy
18%
Radiology
18%
Thorax Radiography
17%
Primary Tumor
15%
Differential Diagnosis
15%
positron emission tomographic scan
15%
Overall Survival
15%
Cross-Sectional Imaging
14%
Progression Free Survival
14%
Arm
14%
Immunity
14%
Awareness
14%
Immune Checkpoint Inhibitor
13%
Nivolumab
13%
Silo-Filler's Disease
13%
Ipilimumab
13%
Pleura Mesothelioma
12%
Thymus Cancer
12%
Recurrent Disease
12%
Patient Care
12%
Clinician
12%
Solid Malignant Neoplasm
12%
Treatment Response
12%
Selinexor
12%
Phase II Trials
12%
Incidental Finding
12%
Fluorodeoxyglucose F 18
12%
Thoracic Cancer
12%
Polyethylene Terephthalate
11%
Infection
11%
Keyphrases
Non-small Cell Lung Cancer (NSCLC)
61%
Lung Cancer
51%
Magnetic Resonance Imaging
36%
Radiologists
30%
Tumor
30%
Selinexor
28%
Multi-arm
25%
Single Center
25%
Computed Tomography
25%
Advanced Solid Tumors
24%
Radiation Therapy
23%
Programmed Death-ligand 1 (PD-L1)
22%
Phase Ib Study
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
19%
Metastatic Disease
18%
Esophageal Adenocarcinoma
17%
Targeted Therapy
17%
Lung
16%
Phase II Trial
16%
Metastatic Tumor
16%
Imaging Findings
16%
International Thymic Malignancy Interest Group (ITMIG)
15%
Thorax
15%
Immune Checkpoint Inhibitors
15%
Chemotherapy
14%
Response Evaluation Criteria in Solid Tumors (RECIST)
14%
Ipilimumab
13%
Mediastinal Mass
13%
Metastasis
13%
Imaging Modalities
13%
Positron Emission Tomography-computed Tomography (PET-CT)
13%
Carboplatin
12%
Nivolumab
12%
Median Progression-free Survival
12%
Mediastinal Compartments
12%
Clinical Outcomes
12%
Thymic Epithelial Neoplasm
12%
ACR Appropriateness Criteria
12%
Advanced or Metastatic
12%
Thoracic CT
12%
Chemoradiation
12%
Incidental
12%
Paclitaxel
12%
Investigational New Drug
12%
Neoplasms
11%
Overall Survival
11%
Imaging Studies
11%
Phase II Study
10%
Clinical Activity
10%
Cross-sectional Imaging
10%